Amanote Research
Register
Sign In
P3.04-28 Can Ipilimumab Restore Immune Response in Advanced NSCLC After Progression on Anti PD1/PDL1 Agents?
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.1735
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
M. Sternschuss
N. Peled
E. Dudnik
O. Rotem
A. Zer
Publisher
Elsevier BV
Related search
P3.04-20 Correlation of Immune-Related Adverse Events and Response From Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.04-25 EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC With PD-L1 <50%
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.04-02 Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.04-15 IDO and Tim3 Gene Expression Is Correlated in NSCLC Patients With Low PDL1 Gene Expression
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.04-24 EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC With PD-L1 ≥50%, a Phase 3 Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.13-28 Heterogeneity, Prevalence and Prognostic Significance of PDL1 Expression in Early Resected NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status With Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Neutrophil Content Predicts Lymphocyte Depletion and Anti-Pd1 Treatment Failure in NSCLC
JCI insight
Medicine
P3.04-26 EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC With PD-L1 <50%
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary